Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amplify Cybersecurity ETF (HACK) vs Eli Lilly And Co (LLY) Price & Performance

Amplify Cybersecurity ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Amplify Cybersecurity ETF vs Eli Lilly And Co — how do they compare? Amplify Cybersecurity ETF trades at $107.82, while Eli Lilly And Co trades at $1,168.23 (market cap $1.02T). The key difference: Eli Lilly And Co pays a 0.6% dividend while Amplify Cybersecurity ETF pays none. Which is the better fit depends on your goals.

HACKLLY
Sector
Sector/ThematicHealth
52-Week High
$114.29$1.24K
52-Week Low
$70.69$625.65
Market Cap
$1.02T
Enterprise Value
$1.06T
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amplify Cybersecurity ETF

HACK trades at $110.08, down 0.86% on the day, with a bullish technical signal driven by moving averages and strong trend momentum (ADX above 60). The ETF benefits from rising cybersecurity spending, which surpassed $300 billion in 2026 (24/7 Wall Street, 2026-07-03), and recently hit a 52-week high (Zacks Investment Research, 2026-05-26). Institutional interest is growing, with D.A. Davidson increasing its stake by 44.8% in Q1 2026 (Defense World, 2026-07-19).

Outlook remains positive due to structural demand for cybersecurity, but risks include sector volatility and reliance on tech spending. The ETF offers exposure to a high-growth theme, yet investors face concentration in tech and sensitivity to corporate budget cycles. Near-term resistance is at $111, with support at $110.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amplify Cybersecurity ETF

HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.

Read more on HACK

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY